Drugs / QVLP
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02236052 | Jul 2014 → Jun 2015 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QVLP | “In the first Phase II trial reported here (NCT02233816), 18-49 year old subjects received 15, 30 or 60 μg/strain of a hemagglutinin-bearing quadrivalent virus-like particle...” PMID 31166987 ↗ Jun 2019 |
| Modality | Vaccine | “Low (≤15 μg/strain) doses of a new plant-derived virus-like-particle (VLP) vaccine candidate have been shown to induce humoral and cellular responses against both homologous...” PMID 31166987 ↗ Jun 2019 |
| Route | Intramuscular | “a single intramuscular injection of plant-based Seasonal VLP Quadrivalent Influenza Vaccine” NCT02236052 ↗ |